Adverse drug reactions in the mouth

Clinics in Dermatology

Volumn 18, Issue 5, 2000, Pages 525-532

  Porter, Stephen R ^a   Scully, Crispian ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMINOSALICYLIC ACID; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLEOMYCIN; CAPTOPRIL; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; FLUOROURACIL; KETOCONAZOLE; LITHIUM; LORAZEPAM; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NICORANDIL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLAMINE; PHENACETIN; PHENOTHIAZINE DERIVATIVE; PYRAZOLONE DERIVATIVE; QUINIDINE; QUININE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

BULLOUS SKIN DISEASE; DRUG ERUPTION; GINGIVA HYPERPLASIA; HUMAN; MOUTH DISEASE; MOUTH ULCER; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND DISEASE; SKIN MANIFESTATION; SKIN PIGMENTATION;

DRUG ERUPTIONS; HUMANS; MOUTH DISEASES; MOUTH MUCOSA; OPPORTUNISTIC INFECTIONS; PHARMACEUTICAL PREPARATIONS;

EID: 0034633111     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(00)00143-7     Document Type: Review

References (160)

1. Oral ulceration and other related disorders
2. Aphthous stomatitis due to captropril
3. Giant oral aphthous ulcers induced by nicorandil
4. Nicorandil-induced severe oral ulceration: A newly recognized drug reaction
5. Medication can induce severe ulcerations
6. An association between recurrent oro-genital ulceration and non-steroidal anti-inflammatory drugs
7. Oral complications of cancer therapies: Prevention and management
8. Alterations in the oral mucosa caused by chemotherapeutic agents
9. Oral complications following neo-adjuvant chemotherapy in patients with head and neck cancer
10. Oral management of the head and neck radiation patient
11. Local antimicrobial therapy of oral mucositis in paediatric patients undergoing bone marrow transplantation
12. Oral lesions in the systemic mycoses
13. Orofacial manifestations of the systemic mycoses
14. HIV: The surgeon's perspective 3: Diagnosis and management of malignant neoplasms
15. Human herpesvirus 8 (Kaposi's sarcoma virus)
16. Systemic pharmacotherapy
17. A guide to drug eruptions
18. Cutaneous reactions to drugs
19. Update on oral lichen planus: Etiopathogenesis and management
20. Oral lichenoid drug eruptions
21. Drug-induced lichen planus
22. Lichen planus-like drug eruption
23. Histopathological discrimination criteria between lichenoid drug eruptions and idiopathic lichen planus: Retrospective study on selected samples
24. Basal cell cytoplasm autoantibodies in oral lichen planus
25. Oral lichen planus is not associated with IgG circulating antibodies to epithelial antigens
26. Sulphydryl drug-induced eruption: A clinical and histological study
27. Immunological aspects of dermal and oral lichen planus
28. An association between HLA DR1 and lichen planus
29. Lichen planus: A theory of pathogenesis
30. Grinspan's syndrome: A drug-induced phenomenon?
31. Lichen planus following procainamide-induced lupus erythematosus
32. Captopril-induced lichen planus pemphigoides with pemphigus-like features. A case report
33. Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus
34. Angiotensin-converting enzyme inhibitor-induced pemphigus: Three case reports and literature review
35. Mechanisms of drug eruptions: Part 1
36. Gaining more insight into the patho-mechanisms of thiol-induced acantholysis
37. Imbalance between plasminogen activator and its inhibitors in thiol-induced acantholysis
38. Drug-induced versus drug-triggered pemphigus
39. Drug-induced pemphigoid: Bullous and cicatricial
40. A props de deu cas d'accidents bulleux dont un cas de pemphigus, dus a la penicillamine
41. Penicillamine-associated pemphigus: Is it really pemphigus?
42. Cicatricial pemphigoid in a D-penicillamine-treated patient with rheumatoid arthritis
43. Combined features of pemphigus and pemphigoid induced by penicillamine
44. Bulles et lesions urticariformes de vascularite allergique aved immunomarquage de type pemphigoide bulleuse lors d'un traitment par penicillamine
45. Penicillamine-induced bullous pemphigoid with pemphigus-like antibodies
46. Drug-induced linear IgA bullous dermatosis: Report of six cases and review of the literature
47. Drug-induced linear IgA disease: Target antigens are heterogeneous
48. Drug-induced lupus. The list of culprits grows
49. Drug-induced lupus
50. Drug-induced lupus erythematosus
51. The clinical utility of antihistone antibodies. Autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus
52. Antinuclear antibodies (ANA) and complement fixing ANA in systemic connective tissue diseases
53. HLA-DR7 in association with chlorpromazine-induced lupus anticoagulant (LA)
54. Autoantibody to the nucleosome subunit (H2A-H2B) is an early and ubiquitous feature of lupus-like conditions
55. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme
56. Immunologically mediated disease
57. Toxic epidermal necrolysis (the scalded skin syndrome). A reappraisal
58. Toxic epidermal necrolysis
59. Oral manifestations of toxic epidermal necrolysis (TEN) in patients with AIDS: Report of five patients
60. Skin manifestations of graft-versus-host reaction following bone marrow transplantation
61. Acute and AIDS-related oral candidosis
62. Candida and oral candidosis: A review
63. Oral hairy leukoplakia: Clinicopathological features, pathogenesis, diagnosis and clinical significance
64. Human papilloma viruses (HPV) and oral health and disease
65. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients
66. Oral lesions in organ transplant patients
67. Oral mucosal pigmentation resulting from antimalarial therapy
68. Gingival pigmentation associated with antimalarial drugs
69. Amodioquine-induced oral pigmentation - A light and electron microscopic study
70. Drug-induced palatal pigmentation
71. Less common oral lesions associated with HIV infection: Prevalence and classification
72. Oral melanotic macules in patients infected with human immunodeficiency virus
73. Epithelial melanosis of the gingiva possibly resulting from the use of oral contraceptives
74. Intravenous and oral amiodarone for children with arrhythmias
75. Minocycline-induced intraoral pharmacogenic pigmentation: Case reports and review of the literature
76. Lingual hyperpigmentation associated with minocycline therapy
77. Melanocanthoma: A rare cause of oral hyperpigmentation
78. Case report: Ionisation tendency of a metal alloy in the oral environment
79. Periodontal aspects of systemic disease. A system of classification
80. Quinke's disease: Non-hereditary angioneurotic edema of the uvula
81. Angioedema and swellings of the orofacial region
82. Hypersensitivity and anaphylaxis
83. ACE inhibitor-induced angioedema. Incidence, prevention and management
84. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema
85. Lingual angio-edema after perindopril use
86. Fatal angioedema associated with lisinopril
87. Epidemiological study of angioedema and ACE inhibitors
88. Angioedema of ACE inhibitors
89. Angiotensin-converting enzyme (ACE) inhibitors and their implications for the dental surgeon
90. Idiopathic plasmacytosis of the oral and supraglottic mucosa
91. Plasma cell orofacial musositis: Report of a case and review of the literature
92. Plasmacytosis managed with photodynamic therapy
93. Medication-induced gingival overgrowth
94. Selected side effects. 7. Phenytoin and gingival overgrowth
95. Cyclosporin and the gingival tissues
96. Gingival hyperplasia: Side effect of nifedipine and diltiazem
97. Hyperplastic gingivitis during diltiazem therapy
98. Gingival overgrowth induced by diltiazem
99. Verapamil-induced gingival overgrowth: A clinical, histologic, and biochemic approach
100. Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth
101. The effect of verapamil on the prevalence and severity of cyclosporine-induced gingival overgrowth in renal allograft recipients
102. Gingival hyperplasia: Interaction between cyclosporin-A and nifedipine? A case report
103. The distribution of gingival overgrowth in organ transplant patients
104. Pathogenesis of drug-induced gingival overgrowth: A review of studies in the rat model
105. Kaposi's sarcoma in cyclosporin-induced gingival hyperplasia
106. Carcinoma arising in cyclosporin-induced gingival hyperplasia
107. Tranexamic acid-associated ligneous conjunctivitis with gingival and peritoneal lesions
108. Gingival hyperplasia induced by erythromycin
109. Hyperplastic gingivitis in a child receiving sodium valproate
110. Gingival hyperplasia due to sodium valproate
111. Phenobarbital-induced gingival overgrowth? Report of 2 cases and complications in management
112. Vigabatrin-induced gingival overgrowth
113. Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction
114. Drug-induced disorders of taste
115. Chemosensory physiology and disorders
116. Disturbances of taste and smell induced by drugs
117. Converting enzyme inhibitors in the treatment of hypertension
118. HIV topic update: Protease inhibitor therapy and oral health care
119. Bismuth-containing single antibiotic 1-week triple therapy for Helicobacter pylori eradication
120. Taste loss to terbinafine: A case-control study of potential risk factors
121. Changes in taste associated with intravenous administration of pentamidine
122. Loss of taste associated with isotretinoin
123. What to do about halitosis
124. Scalded mouth caused by angiotensin-converting enzyme inhibitors
125. Lisinopril-induced scalded mouth syndrome
126. Oral and genital tardive pain syndromes
127. Trigeminal sensory neuropathy induced by interferon-alpha therapy
128. Orofacial complications of chemotherapy for breast cancer
129. Long standing trigeminal sensory neuropathy of nontraumatic cause
130. Drug-induced movement disorders
131. Neuroleptic intolerance
132. Drug-induced movement disorders
133. Salivary gland enlargement and phenylbutazone
134. Salivary gland enlargement and phenylbutazone
135. Salivary gland enlargement caused by sulfisoxazole
136. Salivary gland swelling following niaproxen therapy
137. Salivary gland enlargement following renografin injection may be secondary to hypersensitivity
138. Salivary gland enlargement caused by intravenous iodinated contrast medium. Description of a case
139. Clozapine and the development of salivary gland swelling: A case study
140. Prevalence of perceived symptoms of drug mouth in an adult Swedish population - Relation to age, sex and pharmacotherapy
141. Acquired salivary dysfunction. Drugs and radiation
142. Xerostomia: Prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists
143. Xerostomia, xerogenic medications and food avoidances in selected geriatric groups
144. Salivary function and hypertension: A review of the literature and a case report
145. Nutritional implications of xerostomia and rampant caries caused by serotonin re-uptake inhibitors - A case study
146. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity
147. Venlafaxine: A heterocyclic antidepressant
148. Long-term safety and clinical acceptibility of venlafaxine and imipramine in outpatients with major depression
149. Omeprazole and dry mouth
150. Anti-retroviral drugs - Implications for dental prescribing
151. Xerostomia associated with didanosine
152. Xerostomia associated with didanosine
153. Trospium chloride versus oxybutynin: A randomised, double-blind multi-centre trial in the treatment of detrusor hyper-reflexia
154. Phase II study of elliptinium acetate salvage treatment of advanced breast cancer
155. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states
156. Orofacial disease: Update for the dental clinical team: 8. Salivary complaints